Daclizumab HYP: Another Option in Treating Relapsing Multiple Sclerosis

Daclizumab was more efficacious than interferon beta-1a at reducing relapse rate in a phase 3 randomized trial.

Daclizumab high-yield process (HYP) is an investigational humanized monoclonal antibody that targets CD25 and modulates interleukin-2 signaling, which is considered a pathogenic pathway in multiple sclerosis (MS). Researchers report results of a phase III, randomized, double-blind, active-controlled, international, industry-sponsored trial of daclizumab. The researchers enrolled 1841 people with relapsing–remitting MS aged 18 to 55 with mild-to-moderate disability (Expanded Disability Status Scale Score 0–5 and evidence of recent disease activity). Participants were randomized 1:1 to daclizumab HYP 150 mg subcutaneously every 4 weeks or intramuscular interferon beta-1a 30 µg once weekly, with a double-dummy design. Treatment lasted 96 to 14…

Reviewing Author

Jeffrey M. Gelfand, MD, MAS

Disclosures

12/1/14I recently attended a trial investigator meeting as a sub-investigator for a clinical trial sponsored by Medimmune.

Jeffrey M. Gelfand, MD, MAS

Disclosures

12/1/14I recently attended a trial investigator meeting as a sub-investigator for a clinical trial sponsored by Medimmune.

Daclizumab HYP: Another Option in Treating Relapsing Multiple Sclerosis

Topics

Reviewing Author